Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T09:46:25.286Z Has data issue: false hasContentIssue false
  • English
  • Français

Increased ischaemia-modified albumin is associated with inflammation in acute rheumatic fever

Published online by Cambridge University Press:  10 May 2013

Zehra Karataş ,
Tamer Baysal ,
Fatih Şap ,
Hayrullah Alp  and
Idris Mehmetoğlu
Zehra Karataş
Affiliation:
Department of Paediatric Cardiology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
Tamer Baysal
Affiliation:
Department of Paediatric Cardiology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
Fatih Şap
Affiliation:
Department of Paediatric Cardiology, Konya Training and Research Hospital, Konya, Turkey
Hayrullah Alp
Affiliation:
Department of Paediatric Cardiology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
Idris Mehmetoğlu
Affiliation:
Department of Biochemistry, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Ischaemia-modified albumin, a novel biochemical marker for tissue ischaemia, was found to be associated with oxidative stress. The purpose of this study was to assess the role of ischaemia-modified albumin in the diagnosis of acute rheumatic fever and also to evaluate the ischaemia-modified albumin levels in children with heart valve disease. Methods: The study groups, aged 5–18 years, consisted of 128 individuals – 40 with acute rheumatic fever, 35 with congenital heart valve disease, 33 with chronic rheumatic heart disease, and 20 healthy control subjects. Results: The ischaemia-modified albumin, erythrocyte sedimentation rate, and C-reactive protein levels of the acute rheumatic fever group were significantly higher than those in the chronic rheumatic heart disease, congenital heart valve disease, and control groups, separately (p < 0.001). The ischaemia-modified albumin levels in both carditis and isolated arthritis subgroups of children with acute rheumatic fever were significantly higher than in the control group (p < 0.001, p < 0.01, respectively). However, there was no statistically significant difference between the chorea subgroup and control subjects. In addition, significant correlations were observed between ischaemia-modified albumin and acute phase reactants of patients with acute rheumatic fever (p < 0.001 for both erythrocyte sedimentation rate and C-reactive protein). The ischaemia-modified albumin levels of chronic rheumatic heart disease, congenital heart valve disease, and control subjects were similar. Conclusions: The increased level of ischaemia-modified albumin in children with acute rheumatic fever seems to be associated with inflammation. However, further studies are needed to provide stronger evidence.

Keywords

Acute rheumatic feverchildrenchronic rheumatic heart diseasecongenital heart valve diseaseischaemia-modified albumin
Type
Original Articles
Information
Cardiology in the Young , Volume 24 , Issue 3 , June 2014 , pp. 430 - 436
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Lincoln, J, Yutzey, KE. Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res A Clin Mol Teratol 2011; 91: 526–534.CrossRefGoogle ScholarPubMed
2. O'Brien, KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006; 26: 1721–1728.CrossRefGoogle Scholar
3. Davutoglu, V, Celik, A, Aksoy, M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005; 14: 251–256.Google Scholar
4. Gölbasi, Z, Uçar, O, Keles, T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002; 4: 593–595.Google Scholar
5. Chopra, P, Gulwani, H. Pathology and pathogenesis of rheumatic heart disease. Indian J Pathol Microbiol 2007; 50: 685–697.Google ScholarPubMed
6. Kumar, V, Ganguly, NK, Sethi, AK, Anand, IS, Verma, J, Wahi, P. Role of oxygen free radicals generated by blood monocytes and neutrophils in the pathogenesis of rheumatic fever and rheumatic heart disease. J Mol Cell Cardiol 1990; 22: 645–651.Google Scholar
7. Oran, B, Atabek, E, Karaaslan, S, Reisli, İ, Gultekin, F, Erkul, İ. Oxygen free radicals in children with acute rheumatic fever. Cardiol Young 2001; 11: 285–288.Google Scholar
8. Bar-Or, D, Curtis, G, Rao, N, Bampos, N, Lau, E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42–47.CrossRefGoogle ScholarPubMed
9. Roy, D, Quiles, J, Gaze, DC, Collinson, P, Kaski, JC, Baxter, GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92: 113–114.CrossRefGoogle ScholarPubMed
10. Sbarouni, E, Georgiadou, P, Voudris, V. Ischemia modified albumin changes – review and clinical implications. Clin Chem Lab Med 2011; 49: 177–184.CrossRefGoogle ScholarPubMed
11. Uner, A, Sal, E, Doğan, M, et al. Investigation of oxidant and antioxidant pathway changes in acute rheumatic fever. Acta Cardiol 2010; 65: 53–57.Google Scholar
12. Kurban, S, Mehmetoglu, I, Oran, B, Kiyici, A. Homocysteine levels and total antioxidant capacity in children with acute rheumatic fever. Clin Biochem 2008; 41: 26–29.Google Scholar
13. Chiu-Braga, YY, Hayashi, SY, Schafranski, M, Messias-Reason, IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006; 109: 275–276.Google Scholar
14. Chen, MC, Chang, JP, Liu, WH, et al. Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement. Clin Biochem 2009; 42: 943–948.Google Scholar
15. Ahmed, MI, Gladden, JD, Litovsky, SH, et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol 2010; 55: 671–679.Google Scholar
16. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. Special Writting Group of the Comittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Counsil on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268: 2069–2073. Erratum in: JAMA, 1993; 269: 476.CrossRefGoogle Scholar
17. Sahn, DJ, DeMaria, A, Kisslo, J, Weyman, A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.Google Scholar
18. Rheumatic fever and rheumatic heart disease, World Health Organ Tech Rep Ser, 2004; 923: 1–122.Google Scholar
19. Cheitlin, MD, Armstrong, WF, Aurigemma, GP et al. American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108: 1146–1162.CrossRefGoogle Scholar
20. Helske, S, Kupari, M, Lindstedt, KA, Kovanen, PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007; 18: 483–491.Google Scholar
21. Mohler, ER III, Gannon, F, Reynolds, C, Zimmerman, R, Keane, MG, Kaplan, FS. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522–1528.Google Scholar
22. Bar-Or, D, Winkler, JV, Vanbenthuysen, K, Haris, L, Lau, E, Hetzel, F. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 2001; 141: 985–991.Google Scholar
23. Sinha, MK, Vazquez, JM, Calvino, R, Gaze, DC, Collinson, PO, Kaski, JC. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart 2006; 92: 1852–1853.Google Scholar
24. Senes, M, Kazan, N, Coşkun, O, Zengi, O, Inan, L, Yücel, D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007; 44: 43–47.CrossRefGoogle ScholarPubMed
25. Dundar, ZD, Cander, B, Gul, M, Karabulut, KU, Girisgin, S. Serum ischemia-modified albumin levels in an experimental acute mesenteric ischemia model. Acad Emerg Med 2010; 17: 1233–1238.CrossRefGoogle Scholar
26. Kaefer, M, Piva, SJ, De Carvalho, JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010; 43: 450–454.Google Scholar
27. Borderie, D, Allanore, Y, Meune, C, Devaux, JY, Ekindjian, OG, Kahan, A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004; 50: 2190–2193.Google Scholar
28. Cakir, M, Karahan, SC, Mentese, A, et al. Ischemia-modified albumin levels in children with chronic liver disease. Gut Liver 2012; 6: 92–97.Google Scholar
29. Albarello, K, Dos Santos, GA, Bochi, GV, et al. Ischemia modified albumin and carbonyl protein as potential biomarkers of protein oxidation in hemodialysis. Clin Biochem 2012; 45: 450–454.Google Scholar
30. Vincent, HK, Taylor, AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006; 30: 400–418.Google Scholar
31. Duarte, MM, Rocha, JB, Moresco, RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009; 42: 666–671.CrossRefGoogle ScholarPubMed
32. Fidan, E, Mentese, A, Kavgaci, H, et al. Increased ischemia-modified albumin levels in patients with gastric cancer. Neoplasma 2012; 59: 393–397.Google Scholar
33. Oran, B, Coban, H, Karaaslan, S, Atabek, E, Gurbilek, M, Erkul, I. Serum cardiac troponin-I in active rheumatic carditis. Indian J Pediatr 2001; 68: 943–944.Google Scholar
34. Williams, RV, Minich, LL, Shaddy, RE, Veasy, LG, Tani, LY. Evidence for lack of myocardial injury in children with acute rheumatic carditis. Cardiol Young 2002; 12: 519–523.Google Scholar
35. Valko, M, Leibfritz, D, Moncol, J, Cronin, MT, Mazur, M, Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44–84.Google Scholar
36. Gaze, DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009; 24: 333–341.Google Scholar
37. Rabus, M, Demirbağ, R, Sezen, Y, et al. Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. Turk Kardiyol Dern Ars 2008; 36: 536–540.Google ScholarPubMed